195 related articles for article (PubMed ID: 8245881)
21. Susceptibility of varicella-zoster virus to thymidine analogues.
Machida H
Biken J; 1986 Mar; 29(1):1-6. PubMed ID: 3022708
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in herpesvirus therapy.
Naesens L; De Clercq E
Herpes; 2001 Mar; 8(1):12-6. PubMed ID: 11867011
[TBL] [Abstract][Full Text] [Related]
24. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir.
Machida H; Nishitani M
Microbiol Immunol; 1990; 34(4):407-11. PubMed ID: 2163486
[TBL] [Abstract][Full Text] [Related]
25. Selective anti-herpesvirus agents.
De Clercq E
Antivir Chem Chemother; 2013 Jan; 23(3):93-101. PubMed ID: 23343513
[TBL] [Abstract][Full Text] [Related]
26. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
Han H; de Vrueh RL; Rhie JK; Covitz KM; Smith PL; Lee CP; Oh DM; Sadée W; Amidon GL
Pharm Res; 1998 Aug; 15(8):1154-9. PubMed ID: 9706043
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
28. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
29. [Drug of the month. Valaciclovir (Zelitrex)].
Piérard GE; Nikkels AF
Rev Med Liege; 1997 Aug; 52(8):553-5. PubMed ID: 9381007
[No Abstract] [Full Text] [Related]
30. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrug.
McGuigan C; Slater MJ; Parry NR; Perry A; Harris S
Bioorg Med Chem Lett; 2000 Apr; 10(7):645-7. PubMed ID: 10762044
[TBL] [Abstract][Full Text] [Related]
32. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.
Anand BS; Katragadda S; Nashed YE; Mitra AK
Curr Eye Res; 2004; 29(2-3):153-66. PubMed ID: 15512962
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetic basis of oral valacyclovir treatment of herpes simplex virus (HSV) or varicella zoster virus (VZV) meningitis, meningoencephalitis or encephalitis in adults.
Cunha BA; Baron J
J Chemother; 2017 Apr; 29(2):122-125. PubMed ID: 26239190
[No Abstract] [Full Text] [Related]
34. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.
Machida H; Watanabe Y
Microbiol Immunol; 1991; 35(2):139-45. PubMed ID: 1653394
[TBL] [Abstract][Full Text] [Related]
35. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
[TBL] [Abstract][Full Text] [Related]
36. Valaciclovir: a review of its use in the management of herpes zoster.
Ormrod D; Goa K
Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.
Thackray AM; Field HJ
J Infect Dis; 1996 Feb; 173(2):291-9. PubMed ID: 8568288
[TBL] [Abstract][Full Text] [Related]
38. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.
Balzarini J; Haller-Meier F; De Clercq E; Meier C
Antivir Chem Chemother; 2001 Sep; 12(5):301-6. PubMed ID: 11900349
[TBL] [Abstract][Full Text] [Related]
39. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
40. Valacyclovir as Initial Treatment for Acute Retinal Necrosis: A Pharmacokinetic Modeling and Simulation Study.
Liu T; Jain A; Fung M; Vinnard C; Ivaturi V
Curr Eye Res; 2017 Jul; 42(7):1035-1038. PubMed ID: 28358222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
